GlassScriptPhysician profile
Michael A Sorace
NPI 1265614168
$6,894.04
in general payments reported to CMS, 2019-2025
25 companies · $1,171 in 2025
The $1,171 reported for 2025 was more than what 78% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,095 · 2020: $187 · 2021: $616 · 2022: $1,294 · 2023: $1,455 · 2024: $1,075 · 2025: $1,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,701.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,162.72 | 2019-2025 | Skyrizi |
| Janssen Scientific Affairs, LLC | $793.58 | 2019-2025 | Tremfya |
| Ucb, INC. | $627.51 | 2019-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $521.36 | 2019-2025 | Siliq, Arazlo |
| Regeneron Healthcare Solutions, INC. | $463.81 | 2022-2024 | Dupixent, Libtayo |
| Genzyme Corporation | $422.56 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $355.38 | 2023-2025 | Sotyktu |
| Lilly USA, LLC | $312.35 | 2019-2024 | |
| Vyne Pharmaceuticals INC. | $261.94 | 2020-2021 | |
| Dermavant Sciences, INC. | $249.99 | 2022-2024 | Vtama |
| Bioventus LLC | $217.48 | 2022-2023 | |
| Pfizer INC. | $197.81 | 2022-2023 | |
| Next Science LLC | $189.18 | 2023 | Blastx, Xperience, Surgx |
| Boston Scientific Corporation | $188.85 | 2021-2022 | |
| Galderma Laboratories, L.P. | $173.05 | 2022-2023 | Aklief |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $148.81 | 2019-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Aclaris Therapeutics, INC. | $124.98 | 2019 | |
| Kyowa Kirin, INC. | $118.21 | 2024 | Poteligeo |
| Incyte Corporation | $109.98 | 2023 | Opzelura |
| Misonix INC | $88.98 | 2019-2020 | |
| Lifenet Health | $69.34 | 2023 | |
| Genentech USA, INC. | $33.18 | 2019 | |
| Biocompatibles, INC. | $28.34 | 2019 | |
| Sun Pharmaceutical Industries INC. | $18.08 | 2024 | |
| Mimedx Group, INC. | $16.57 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sorace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.